Replies to post #559640 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

So far the ones who have made that ‘mistake’ with NWBO each time it has gone up have done quite well.

But you are basically right.

Its not that very difficult next time the SP increases for reasons of near-future revenue aka approval of an RA or other cash influx nontoxic dilutive reasons or hints of a BO then the MC will most likely keep being appreciated.

[Doc logic]

HappyLibrarian,

The reason biotechs are trading stocks for the most part is that pre revenue companies go through cycles of funding, news of noted progress, losses, dilution. Rinse and repeat for years. We bottomed out on the down trend side of a company with expected approvals and future revenue and are now on the uptrend side. This has been pointed out on this board many times. The slowness of the uptrend reflects the slowness of “the process” so stop with blaming NWBO and place angst at the door of “the process” where it clearly belongs.
You intuitively know that there should be a way for patients to gain access to this treatment because of it’s safety profile, multiple sources of reliable data and long known signal of positive effect. However, “the process” offers no opportunity because that would not protect the status quo of steady big pharma revenue and “stability” in the corrupted and geopolitically sensitive markets. Best wishes.

[kabunushi]

Yes, traders can do very well indeed especially so when they are allowed to trade the most volatile stocks on the market with 20-20 hindsight look back trading. I could have been so rich even when paying ST cap gains tax on every trade. But sadly my brokers don't allow that technique.

[biosectinvestor]

Pre-commercial biotechs are notoriously volatile and underfunded before they are fully validated. They are also manipulated by long-short hedge funds. This is still substantially up for me over the 5 years or so period I have been in and I can't complain.

The reality is even in the best but most volatile stock of the century, there are many investors who only buy chasing them on a run, and sell when they are down. Some of those people will even brag that they are a Tesla or Apple or other investor, to imply they've been successful, when in fact they've been a disaster of an investor. That's the nature of people talking about investments. There are people who will lose money, no matter what, because they think they know better than anyone else and they TRADE when they shouldn't. That is frequently not the fault of a particular stock, but the investor not knowing their own limitations. Some investors should just dollar cost average index funds, not volatile, pre-commercial biotechs like this one, and many should not trade stocks at all, just accumulate those indexes. It's not for everyone to invest in this sector. It just isn't.